Ascendis Pharma Swings to Profit, Reports €1.4B Equity Boost in H1 2026
Danish biopharma posts strong earnings turnaround with €13.27 per share in H1 as convertible note redemption reshapes balance sheet.
Ascendis Pharma Swings to Profitability in First Half
Ascendis Pharma A/S reported a significant turnaround to profitability in the first half of 2026, posting diluted earnings per share of €12.73 for the six months ended June 30, compared to a loss of €2.22 per share in the same period of 2025 (6-K filing, 2026-08-13). The Danish biopharmaceutical company, which trades on Nasdaq under the ticker ASND with a market capitalization of approximately $16 billion, filed its unaudited condensed consolidated interim financial statements on August 13, 2026.
For the second quarter alone, the company reported diluted earnings per share of €2.83, reversing a €0.82 loss in Q2 2025 (6-K filing, 2026-08-13). The strong performance coincided with new drug approvals and a significant restructuring of the company's capital structure.
Balance Sheet Transformation
Ascendis Pharma's equity position improved dramatically during the six-month period, rising from negative €162.8 million as of January 1, 2026, to positive €1.44 billion as of June 30, 2026 (6-K filing, 2026-08-13). This €1.6 billion swing was driven in part by a substantial increase in share premium, which rose from €2.53 billion to €3.30 billion over the period.
The company's accumulated deficit also narrowed considerably, from €2.70 billion at the start of the year to €1.88 billion by June 30 (6-K filing, 2026-08-13).
Convertible Notes Conversion
On May 6, 2026, Ascendis completed the optional redemption of all outstanding 2.25% convertible notes due 2028. All noteholders surrendered their notes for conversion, with the company delivering 3,635,813 ordinary shares plus cash for fractional shares (6-K filing, 2026-08-13). The conversion settled current liabilities totaling €719.4 million as of the conversion date, with no impact on profit or loss.
For the six-month period, total share capital increased by 4,212,518 shares, with 3,635,813 shares related to the convertible note redemption (6-K filing, 2026-08-13). As of June 30, 2026, Ascendis had 66,189,926 fully paid shares outstanding at a nominal value of DKK 1.
Tax Asset Recognition and FDA Approval
The company recognized all deferred tax assets as of June 30, 2026, totaling €699.3 million (6-K filing, 2026-08-13). Management determined it is "probable that future taxable profits will be available" based on expected continued global commercial growth, particularly from YORVIPATH revenue.
In February 2026, the FDA granted accelerated approval for YUVIWEL (navepegritide), "the first and only once-weekly treatment" for increasing linear growth in children aged 2 and older with achondroplasia and open epiphyses (6-K filing, 2026-08-13).
The company's cash and cash equivalents increased to €812.3 million as of June 30, 2026, from €616.0 million at the beginning of the year (6-K filing, 2026-08-13).
According to MarginX data, recent insider activity includes purchases by directors Scott Thomas Smith and Jean Jacques Bienaime. The company is expected to report Q2 2026 results on September 4, 2026.
This article was generated by MarginX from the 6-K filing on 2026-08-13. It is not investment advice.